Completed × INDUSTRY × Lymphoma, Mantle-Cell × Clear all
NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

Phase 1/2 Completed
169 enrolled
NCT02924402 2024-11-13

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Xencor, Inc.

Phase 1 Completed
154 enrolled
NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled
NCT03833180 2024-01-12

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Completed
91 enrolled
NCT00002663 2023-02-13

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Atara Biotherapeutics

Phase 1/2 Completed
58 enrolled 18 charts